Stock DBI DEUTSCHE BIOTECH INNOVATIV AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Deutsche Biotech Innovativ AG Deutsche Boerse AG

Equities

DBI

DE000A0Z25L1

Biotechnology & Medical Research

Delayed Deutsche Boerse AG
Other stock markets
 15:13:44 2023-09-26 EDT 		5-day change 1st Jan Change
5.05 EUR -.--% Intraday chart for Deutsche Biotech Innovativ AG -.--% -.--%
2023 Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2018 Adrenomed AG announced that it has received €24.2 million in funding from Deutsche Biotech Innovativ AG, Wellington Ventures, HBM Healthcare Investments Ltd., and other investors CI

Business Summary

Deutsche Biotech Innovativ AG, formerly Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The Company's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.

Number of employees: 1

Sales per Business

EUR in Million2018Weight2019Weight Delta
Investment and Related Activities
100.0 %
0 100.0 % 0 100.0 % -91.66%

Sales per region

EUR in Million2018Weight2019Weight Delta
Germany
100.0 %
0 100.0 % 0 100.0 % -91.66%

Managers

Managers TitleAgeSince
Bernd Wegener CEO
 Chief Executive Officer 76 08-12-31
Metod Miklus COO
 Chief Operating Officer 65 19-10-06

Members of the board

Members of the board TitleAgeSince
Bernd Wegener CEO
 Chief Executive Officer 76 08-12-31
Metod Miklus COO
 Chief Operating Officer 65 19-10-06
Renke Lührs CHM
 Chairman 64 11-02-14
Eva Gardyan-Eisenlohr BRD
 Director/Board Member - -
Siegmund Karasch BRD
 Director/Board Member 59 18-07-04

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 947,296 937,823 ( 99.00 %) 0 99.00 %

Shareholders

NameEquities%Valuation
HINKEL & Cie. Vermögensverwaltung AG
0.8182 %
7,751 0.8182 % 35 326 €

Company contact information

Deutsche Biotech Innovativ AG

Neuendorfstrasse 15a

16761, Hennigsdorf

+49 3302 20 77 824

http://www.dbi-ag.de
address Deutsche Biotech Innovativ AG(DBI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.70% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.02% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.97% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.32% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.40% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.51% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DBI Stock
  4. DBI Stock
  5. Company Deutsche Biotech Innovativ AG